Global Information
회사소개 | 문의 | 비교리스트

세계의 뇌종양 치료제 시장(2019-2023년)

Global Brain Tumor Therapeutics Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 05월 상품 코드 851217
페이지 정보 영문 126 Pages
가격
US $ 2,500 ₩ 2,971,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,565,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,753,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,942,000 PDF (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 뇌종양 치료제 시장(2019-2023년) Global Brain Tumor Therapeutics Market 2019-2023
발행일 : 2019년 05월 페이지 정보 : 영문 126 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

뇌종양의 이환율 상승이 세계 뇌종양 치료제 시장의 주요 성장요인입니다. 많은 뇌종양이 말기에 발견되므로 진단의 지연은 종양의 악성화를 초래합니다. 또한 암의 전이 등도 뇌종양 이환율의 상승에 영향을 미치고 있습니다. 이 시장은 2023년까지 약 12%의 CAGR로 추이할 것으로 예측됩니다.

세계의 뇌종양 치료제(Brain Tumor Therapeutics) 시장을 조사했으며, 시장 개요, 종류·지역별 시장 규모의 추이와 예측, 시장 성장요인 및 저해요인 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 개요

제2장 리포트 범위

제3장 시장 상황

  • 시장 에코시스템
  • 시장 특성
  • 시장 세분화 분석

제4장 시장 규모

  • 시장의 정의
  • 시장 규모
  • 시장 규모 및 예측

제5장 Five Forces 분석

  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 신규 진출의 위협
  • 대체품의 위협
  • 경쟁 상대의 위협
  • 시장 현황

제6장 파이프라인

제7장 시장 세분화 : 종류별

  • 시장 세분화 : 종류별
  • 시장 비교 : 종류별
    • 저분자 치료제
    • 생물학적 제제
  • 시장 기회 : 종류별

제8장 고객 상황

제9장 지역 상황

  • 시장 세분화 : 지역별
  • 시장 비교 : 지역별
    • 북미
    • 유럽
    • 아시아
    • 기타 지역
  • 주요 선도 국가
  • 시장 기회

제10장 의사결정 프레임워크

제11장 성장요인과 과제

  • 시장 성장요인
  • 시장이 해결해야 할 과제

제12장 시장 동향

제13장 벤더 구도

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제14장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG

제15장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제16장 TECHNAVIO 소개

KSA 19.05.29

About this market

The rising prevalence of brain cancer is one of the key factors that will trigger the growth of the market. Most brain tumors are identified only in the late stages. The delay in diagnosis leads to the tumor becoming malignant. Also, factors such as cancer becoming metastasis are associated with the increasing prevalence of brain cancer. Therefore, the morbid nature of the disease, increasing mortality rate and the huge unmet need caused by the rising prevalence of this disease is expected to increase the use of therapeutics for the treatment. Thus, such factors are expected to drive the growth of the market during the forecast period. Technavio's analysts have predicted that the brain tumor therapeutics market will register a CAGR of almost 12% by 2023.

Market Overview

Strategic alliances

The market is expected to witness an increase in the number of strategic alliances between the universities and vendors, during the forecast period, thus adding significant growth to the global brain tumor therapeutics market.

Preference for substitutes

The ease of treatment is expected to increase the demand for the alternating electric field therapy. This is expected to be a major challenge for the growth of the global brain tumor therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the brain tumor therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be concentrated and with the presence of few companies including Bristol-Myers Squibb Co., and Eisai Co. Ltd., the competitive environment is quite intense. Several organizations are focusing on launching various products such as grey armbands, grey rings, and grey ribbon pins to promote the severity and awareness of brain cancer. The rising number of awareness campaigns is expected to result in the early diagnosis of the disease, thereby driving the market growth. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market characteristics analysis
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Global brain tumor therapeutics market pipeline: Overview
  • Exhibit 19: Global brain tumor therapeutics market pipeline: Snapshot
  • Exhibit 20: Type - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by type
  • Exhibit 22: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Customer landscape analysis
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendor landscape analysis
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 53: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 54: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 55: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 56: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 57: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 58: Eisai Co. Ltd. - Vendor overview
  • Exhibit 59: Eisai Co. Ltd. - Business segments
  • Exhibit 60: Eisai Co. Ltd. - Organizational developments
  • Exhibit 61: Eisai Co. Ltd. - Geographic focus
  • Exhibit 62: Eisai Co. Ltd. - Segment focus
  • Exhibit 63: Eisai Co. Ltd. - Key offerings
  • Exhibit 64: Eisai Co. Ltd. - Key customers
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 72: Merck & Co. Inc. - Vendor overview
  • Exhibit 73: Merck & Co. Inc. - Business segments
  • Exhibit 74: Merck & Co. Inc. - Organizational developments
  • Exhibit 75: Merck & Co. Inc. - Geographic focus
  • Exhibit 76: Merck & Co. Inc. - Segment focus
  • Exhibit 77: Merck & Co. Inc. - Key offerings
  • Exhibit 78: Merck & Co. Inc. - Key customers
  • Exhibit 79: Novartis AG - Vendor overview
  • Exhibit 80: Novartis AG - Business segments
  • Exhibit 81: Novartis AG - Organizational developments
  • Exhibit 82: Novartis AG - Geographic focus
  • Exhibit 83: Novartis AG - Segment focus
  • Exhibit 84: Novartis AG - Key offerings
  • Exhibit 85: Novartis AG - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q